Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Total Liabilities (2016 - 2025)

CorMedix's Total Liabilities history spans 13 years, with the latest figure at $420.8 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 1130.91% year-over-year to $420.8 million; the TTM value through Dec 2025 reached $420.8 million, up 1130.91%, while the annual FY2025 figure was $420.8 million, 1130.91% up from the prior year.
  • Total Liabilities for Q4 2025 was $420.8 million at CorMedix, up from $376.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $420.8 million in Q4 2025 and bottomed at $3.9 million in Q1 2021.
  • The 5-year median for Total Liabilities is $8.0 million (2023), against an average of $52.9 million.
  • The largest annual shift saw Total Liabilities plummeted 32.08% in 2021 before it surged 1896.05% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $6.1 million in 2021, then grew by 13.52% to $7.0 million in 2022, then grew by 17.89% to $8.2 million in 2023, then soared by 315.56% to $34.2 million in 2024, then skyrocketed by 1130.91% to $420.8 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Total Liabilities are $420.8 million (Q4 2025), $376.7 million (Q3 2025), and $32.0 million (Q2 2025).